Literature DB >> 21592431

HIV seroconversions among male non-occupational post-exposure prophylaxis service users: a data linkage study.

Anna B Pierce1, Keflemariam Yohannes, Rebecca Guy, Kerrie M Watson, Jude Armishaw, Brian Price, Jennifer F Hoy, Edwina J Wright, Mark A Stoové.   

Abstract

BACKGROUND: Despite widespread prescription of non-occupational post-exposure prophylaxis (NPEP) in Victoria, little is known about subsequent HIV acquisition among NPEP users. We linked the Victorian NPEP Service (VNPEPS) database and the Victorian HIV Surveillance Registry to determine the number, incidence rate and predictive factors of HIV seroconversions among users of the VNPEPS.
METHODS: Records from male patients that received NPEP in the VNPEPS database (n = 1420) between January 2001 and February 2008 were linked with all entries in the Victorian HIV Surveillance Registry up to May 2008.
RESULTS: Sixty-one men who presented to the VNPEPS were identified as HIV seropositive; 16 of these were diagnosed at initial presentation for NPEP. The incidence of HIV seroconversion in males who were HIV seronegative at first presentation for NPEP was 1.27 (95% confidence interval 0.95-1.70) per 100 person-years. There was no association between HIV seroconversion and number of NPEP presentations or age. The median age of seroconversion was 34.6 years.
CONCLUSION: The incidence of HIV infection among men presenting to the VNPEPS is slightly lower than the HIV incidence in NPEP users in a recent Australian cohort study of men who have sex with men, but higher than HIV incidence in general gay male populations. Frequency of NPEP use was not associated with risk of HIV seroconversion. Examination of risk behaviour before and after NPEP use in this population is required to further assess the impact of NPEP availability and use on HIV incidence rates and risk behaviour in Australia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21592431     DOI: 10.1071/SH10063

Source DB:  PubMed          Journal:  Sex Health        ISSN: 1448-5028            Impact factor:   2.706


  6 in total

1.  Subsequent HIV infection among men who have sex with men who used non-occupational post-exposure prophylaxis at a Boston community health center: 1997-2013.

Authors:  Sachin Jain; Catherine E Oldenburg; Matthew J Mimiaga; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2015-01       Impact factor: 5.078

2.  The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.

Authors:  Sachin Jain; Douglas S Krakower; Kenneth H Mayer
Journal:  Clin Infect Dis       Date:  2015-06-01       Impact factor: 9.079

3.  Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.

Authors:  Kenneth H Mayer; Daniel Jones; Catherine Oldenburg; Sachin Jain; Marcy Gelman; Shayne Zaslow; Chris Grasso; Matthew J Mimiaga
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

4.  Differentiating Nonoccupational Postexposure Prophylaxis Seroconverters and Non-Seroconverters in a Community-Based Clinic in Los Angeles, California.

Authors:  Matthew R Beymer; Robert E Weiss; Robert K Bolan; Ryan M Kofron; Risa P Flynn; David L Pieribone; Sonali P Kulkarni; Raphael J Landovitz
Journal:  Open Forum Infect Dis       Date:  2017-04-04       Impact factor: 3.835

5.  Longitudinal trends in HIV nonoccupational postexposure prophylaxis use at a Boston community health center between 1997 and 2013.

Authors:  Sachin Jain; Catherine E Oldenburg; Matthew J Mimiaga; Kenneth H Mayer
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

6.  Queer as F**k: reaching and engaging gay men in sexual health promotion through social networking sites.

Authors:  Alisa Pedrana; Margaret Hellard; Judy Gold; Nadine Ata; Shanton Chang; Steve Howard; Jason Asselin; Olivia Ilic; Colin Batrouney; Mark Stoove
Journal:  J Med Internet Res       Date:  2013-02-07       Impact factor: 5.428

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.